Aptuit acquires Evotec's CPD business

US-based Aptuit is to acquire the chemical and pharmaceutical development (CPD) business of Evotec, which is comprised of an API facility in Oxford, UK and a well-established and recently-expanded parenteral (injectable vials) fill/finish facility in Glasgow, Scotland.

"This acquisition continues Aptuit's momentum as we assemble a complete suite of drug development services in all three major geographies in Europe, North America and Asia," said Michael Griffith, ceo and founder of Aptuit.

"We will leverage those capabilities [in Oxford and Glasgow] to drive our commercial-scale capabilities in India, providing our clients with drug development services from discovery to commercialisation", he added.

Aptuit has also entered into a long-term supply agreement with Evotec to provide both API and the full range of its development services in support of Evotec's proprietary pharmaceutical pipeline.

The CPD business provides small molecule API development labs, kilo labs and pilot plants in Europe.

The production of clinical trial parenteral vials in Glasgow will flow naturally into Aptuit's six global clinical packaging & logistics (CP&L) facilities. This continues the promise of an integrated offering and enhances Aptuit's suite of drug development services, particularly with respect to Aptuit's Bathgate facility a short distance from the Glasgow facility, and Aptuit's Deeside facility in Wales.

Aptuit plans to retain all of the employees of the CPD business and will continue to honour their compensation and benefit packages. Paul McGee, (currently Evotec's senior vice president of chemical development in Oxford) and Sandy Allan (Evotec's senior vice president of formulation sciences in Glasgow) will continue in their existing roles within Aptuit.